Participation in this program may reduce the risk of injury by up to 70%. While much of the injury prevention research has focused on ACL injuries, our program is designed for anyone participating in ...

A special order item will need to ship to our warehouse from the manufacturer before then shipping to you. The estimated delivery range that you see is based on the information that we receive from ...

A special order item will need to ship to our warehouse from the manufacturer before then shipping to you. The estimated delivery range that you see is based on the information that we receive from ...

February 26, 2025—Humacyte, Inc. announced the commercial launch of Symvess, an acellular tissue engineered vessel-tyod (ATEV) indicated for use in adults as a vascular conduit for extremity arterial ...

in lower extremity arteries; the diameter of the artery at the site of the filtration element placement should be between 2.5–7 mm Silk Road Medical Enroute Transcarotid Neuroprotection System Robust ...

Department of Pediatric and Oncological Surgery, University Center of Pediatrics, Central Teaching Hospital, Medical University, Łódź, Poland Department of Molecular Carcinogenesis, Medical University ...

for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible.

INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid ...

Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the ...

(RTTNews) - Humacyte, Inc. (HUMA) announced the commercial launch of Symvess or acellular tissue-engineered vessel, a bioengineered vascular conduit for extremity vascular trauma. The FDA granted ...